Purpose: Next Generation Sequencing (NGS) has detailed the genomic characterization of 86 Diffuse Large B Cell Lymphoma (DLBCL) by identifying recurrent somatic mutations. We 87 set out to design a clinically feasible NGS panel focusing on genes whose mutations hold 88 potential therapeutic impact. Furthermore, for the first time, we evaluated the prognostic value 89 of these mutations in prospective clinical trials. 90 Experimental Design: A Lymphopanel was designed to identify mutations in 34 genes, 91 selected according to literature data and a whole exome sequencing study of 92 relapsed/refractory DLBCL patients. The tumor DNA of 215 patients with CD20+ de novo 93 DLBCL in the prospective, multicenter and randomized LNH-03B LYSA clinical trials was 94 sequenced to deep, uniform coverage with the Lymphopanel. Cell of origin molecular 95 classification was obtained through gene expression profiling with HGU133+2.0 Affymetrix 96 GeneChip arrays. 97 Results: The Lymphopanel was informative for 96% of patients. A clear depiction of DLBCL 98 subtype molecular heterogeneity was uncovered with the Lymphopanel, confirming that 99 Activated B Cell-like (ABC), Germinal Center B-cell like (GCB) and Primary Mediastinal B-100 cell Lymphoma (PMBL) are frequently affected by mutations in NFkB, epigenetic, and JAK-101 STAT pathways respectively. Novel truncating immunity pathway, ITPKB, MFHAS1 and 102 XPO1 mutations were identified as highly enriched in PMBL. Notably, TNFAIP3 and GNA13 103 mutations in ABC patients treated with R-CHOP were associated with significantly less 104 favorable prognoses. 105
2 Translational Relevance 49 50 This is the first Next Generation Sequencing (NGS) study of such a large, prospective cohort 51 using a targeted gene panel, the Lymphopanel, focusing on genes identified as important for 52 lymphomagenesis or whose potential has been pinpointed in Whole Exome Sequencing 53 studies. Particular attention has been paid to the inclusion of actionable targets in the 54 Lymphopanel, highlighting potential candidate patients for novel personalized therapies. This 55 study further details subtype-enriched gene and pathway mutations in order to optimize 56 DLBCL treatment, and highlights several novel, frequent, and actionable mutations, notably 57 in PMBL. In addition, Lymphopanel NGS has enabled the detection of novel clinical and 58 prognostic correlations, potentially impacting treatment decisions. As benchtop sequencers 59 become increasingly available in academic research and routine clinical settings, our study 60 demonstrates the feasibility and impact of NGS with a consensus gene panel in DLBCL 61 patient management, contributing essential information to today's precision therapy era 62 treatment decisions. BCL2 amplification(7). PMBL displays strong molecular similarities to classical Hodgkin 129 Lymphoma (cHL), exhibiting frequent amplifications of JAK2 and deletions of SOCS1 (8, 9) . 130
Arising from B cells at distinct stages of differentiation and maturation, these subtypes are 131 also diverse in clinical presentation, response to immunochemotherapy and outcome, with the 132 ABC subtype having the most unfavorable prognosis(2,7). As targeted therapies become 133 increasingly widespread, it is essential to thoroughly characterize each molecular subtype, in 134 order to ensure optimal care for each patient. Unfortunately, the cell of origin (COO) 135 classification of DLBCL still has relatively little influence on clinical practice, as GEP is 136 poorly transposable to routine diagnosis and surrogate immunohistochemical algorithms 137 remain unreliable(10), although recent techniques offer better bench to bedside 138 translation (11, 12) . 139
Next generation sequencing (NGS) technologies, enabling high-throughput DNA sequencing, 140 have emerged over the past decade and have provided new insights into the genomic 141 characterization of DLBCL by identifying recurrent single nucleotide variants (SNVs), which 142 can be enriched in a particular subtype(13-22). Although DLBCL is defined by widespread 143 genetic heterogeneity, several of the pinpointed recurrent SNVs warrant special interest as 144 they occur in actionable targets and/or correlate with antitumoral response. Equally of note, 145 despite their probable physiopathological relevance, neither the prognostic value of these 146 mutations nor their potential to predict resistance to conventional B-cell lymphoma 147 immunochemotherapy treatment has been properly evaluated in prospective clinical trials. 148 Furthermore, mutation feature analyses have identified activation-induced cytidine deaminase 149 5 some of these recurrent SNVs, rendering the task of distinguishing driver from passenger 151 mutations even more challenging(23). 152
To more feasibly identify molecular subtypes and reach the goal of precision therapy in 153 DLBCL, a limited and clinically relevant panel of target genes must be designed, with efforts 154 made to thoroughly describe the SNVs they harbor. Furthermore, compact sequencers readily 155 available in academic laboratories must be used in order to generalize this practice and apply 156 it to routine clinical disease management. With this idea in mind, we developed a 157
Lymphopanel NGS assay, designed to identify mutations in 34 genes important for 158 lymphomagenesis based on a literature review of WES studies in DLBCL(13,14,20,24) as 159 well as a WES study of relapsed/refractory DLBCL cases(25). In the current study, we 160 sequenced 215 patients with de novo DLBCL enrolled in the prospective, multicenter and 161 randomized LYSA LNH-03B trials, using the Lymphopanel. Our intent was to determine 162 whether the Lymphopanel was informative enough to identify targetable SNVs and/or 163 pathway mutations that might alter treatment decisions, highlight subtype-specific mutational 164 profiles, distinguish genes impacted by AID, and potentially foretell clinical outcome. (Table S3 ). 13 965 variants were filtered for quality, SNPs and functional relevance, leading to 1064 217 (7.6%) variants ultimately validated (Table S5 and Figure S1 ). The Lymphopanel 218
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on January 29, 2016. © 2016 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 7 informativity was of 96%, with 206 patients (78 GCB, 80 ABC, 30 "other" and 18 PMBL) 219 presenting at least one variant. All genes in the Lymphopanel were informative for at least 220 one patient, with the number of variants per gene ranging from one to 124. Gene mutation 221 frequencies in the total cohort and by subtype are presented in Figure 1 . 222
We subdivided the genes targeted by the Lymphopanel into eight specific pathways ( Figure 2 , 223 Table S3 ). As expected, we confirmed that the ABC subtype is dominated by NFkB pathway 224 mutations (45% of total variants), followed by epigenetic regulation pathway mutations 225 (20.2% of total variants) ( Figure 2A ), whereas the GCB subtype is mostly characterized by 226 mutations in the epigenetic regulation pathway (32.3% of total variants) and the apoptosis/cell 227 cycle pathway (26.3% of total variants) ( Figure 2B ). Mutations in the JAK-STAT, immunity 228 and apoptosis/cell cycle pathways were prevalent in PMBL (29.1%, 20.9% and 20.9% of total 229 variants respectively) ( Figure 2C ). Interestingly, PMBL presented a significantly higher 230 number of variants per sample than the other subtypes combined (p=2.76x10 -5 , Figure S3 ). 231
The "other" subtype showed a fairly hybrid spectrum of pathway mutations ( Figure 2D ), 232 perhaps suggesting the involvement of the three main subtypes, rather than the existence of a 233 distinct entity. 234
We sought to assess the impact of AID involvement in the Lymphopanel genes (detailed in 235 Supplementary Methods and Figure S4 ). Genes with an AID mutation frequency superior to 236 the average of that of the Lymphopanel are presented in Table S6 . Previously identified SHM 237 targets in DLBCL among these genes include MYC, PIM1, IRF4, BCL2, SOCS1 and 238 CIITA(23). Potentially novel SHM targets include MFHAS1, PRDM1, GNA13, MYD88, 239 ITPKB and NOTCH2. There was no significant difference in AID involvement between 240 DLBCL subtypes. 241 242
Lymphopanel NGS identifies mutations with potential treatment impact 243
The Lymphopanel included genes whose mutations could serve to stratify patients according 244 to treatment options. This includes actionable mutations, currently targeted by precision 245 therapies, highlighted in Figure 1 , as well as mutations whose presence might call into 246 question the use of certain targeted therapy options. 247
Recent results have shown that doubly mutated MYD88/CD79B patients are significantly 248 more responsive to single therapy Ibrutinib, a BTK inhibitor, highlighting the importance of 249 targeted NGS for DLBCL patients in the clinical setting(28). Furthermore, the presence of 250 CARD11 and TNFAIP3 mutations has been shown to lead to decreased activity of both 251 CD79B mutations were identified in 10.7% of total patients, slightly less than previously 258 reported, but were significantly enriched in ABC DLBCL (24.7%, FDR=3.2x10 -5 ), 259 corroborating previous studies(13,31). Of note, two (11.8%) MYD88 L265P mutated ABC 260 patients were CARD11 mutated and two were TNFAIP3 mutated, potentially diminishing the 261 effect of Ibrutinib and Sotrastaurin, while six (35.3%) were PRDM1 mutated ( Figure S6 ). 262 ABC cells have been shown to be addicted to IRF4 activity (32), responsible for 263 Lenalidomide treatment response. 21 IRF4 variants were discovered in 7.9% of patients 264 (13.6% of ABC, 4.8% of GCB, 0% of "other" and 11.1% of PMBL) ( Figure 1 ). Although the 265 impact on expression of these mutations was not analyzed, only one IRF4 variant was a stop-266 gain mutation, indicating that expression is most likely at least conserved. Most of the non-267 synonymous SNVs were clustered around amino acid positions 18 (two S18 variants and two 268 G20 variants) and 99 (four C99R variants, SIFT scores=0) ( Figure 4 ). Interestingly, IRF4 269 mutations were almost equally frequent in PMBL and ABC in our cohort. Although IRF4 270 addiction has not been demonstrated in PMBL, this predilection for IRF4 mutations, added to 271 the well-known high expression of IRF4 in this subtype, may suggest a potential role for 272
Lenalidomide treatment in this subtype as well, calling for further investigation of these 273 mutations' effects. 274
Recently, small molecule inhibitors of PIM kinases have been developed and studied in 275 DLBCL. In our cohort, PIM1 mutations were significantly skewed toward ABC (33.3%, 276 FDR=3.3x10 -5 ) in our cohort and represented 20.2% of ABC variants (Figures 2A, 3 and 277 S5A). Of note, truncating PIM1 variants were predominant in ABC patients (13 of 14 278 identified). Interestingly, DLBCL sensitivity to PIM kinase inhibitors is not correlated with 279 the level of PIM kinase expression (33), suggesting that even expression-modifying PIM1 280 mutations might not necessarily hamper the efficacy of PIM1 inhibitors, although this remains 281 to be verified. In any case, the high frequency of PIM1 mutations in our cohort seems to 282 justify the pre-screening of PIM kinase inhibitor candidate patients by PIM1 sequencing, in 283 order to identify those most likely to benefit from this targeted therapy. 284
The most highly mutated gene in GCB, BCL2(34), can notably be targeted by BH3-mimetics. 285
Among our GCB cohort, BCL2 was the third most frequently mutated gene (24.1%, 286
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indicating that BH3 mimetic activity would not be hampered in these patients ( Figure S7 ). 289
Targeting epigenetic changes is also being increasingly explored in the realm of tailored 290 therapy, notably among the GCB subtype, justifying the inclusion of genes such as EZH2, 291 CREBBP, KMT2D and EP300 within the Lymphopanel. In our cohort, 18.1% of GCB patients 292 were EZH2 mutated, mostly at the Y641 hotspot, and EZH2 mutations were enriched in GCB 293 (FDR=1.8x10 -3 ), as observed in previous studies, with no EZH2 mutated ABC patients (13) 294 ( Figures 3 and S5B ). Interestingly, one PMBL patient presented an EZH2 Y641 mutation, 295
adding to the debate of which DLBCL subtypes might benefit from EZH2 inhibitor 296 treatment(26). CREBBP mutations were identified in 31.3% of GCB patients and 6.2% of 297 ABC patients, corroborating previous studies(17), but were also found in 24.2% of "other" 298 and 11.1% of PMBL (Figures 1 and S5 ). KMT2D mutations, evenly distributed throughout the 299 coding sequence, were identified in 40.9% of our cohort, with KMT2D being the most 300 frequently mutated gene in all subtypes except PMBL (Figure 1 ). Of the 124 variants, 78 were 301 truncating mutations, indicating bias toward loss of protein expression. 302
Mutations of master regulators TP53 and MYC showed no significant difference in subtype 303 distribution in our cohort (Figure 3) . TP53 variants were present in 14.9% of total patients 304 (slightly less than previously reported(13,35)) ( Figure 1 ) and several recurrent variants were 305 identified, including six R248 variants, shown to be loss of function mutants in DLBCL(35). 306
As for MYC, we discovered mutations in 6.5% of total patients (4.9% of ABC, 9.6% of GCB, 307 3% of "other" and 5.6% of PMBL). No mutations were identified at the known hotspots in 308 Burkitt Lymphoma (BL), including S62 and T58. 309
Finally, although frequent mutations are most enticing for therapeutic potential, rare 310 mutations can also be potentially very effectively actionable. For instance, BRAF and 311 NOTCH1 mutations have been identified as rare but functionally relevant in DLBCL(13). In 312 our cohort, we identified one patient with an activating V600E BRAF variant. As for 313 NOTCH1, ten patients in our cohort presented mutations (Figure 1 ). TCF3 was mutated in 314 three patients, all of whom harbored a pathogenic N551K variant, which has shown altered 315 DNA-binding specificity(36). The negative regulator of TCF3, ID3, was mutated in 4.7% of 316 patients (Figure 1) , with most variants affecting the HLH domain ( Figure S7 ), potentially 317 impairing its ability to inactivate TCF3, as shown in BL(36). ID3 and TCF3 mutations have 318 recently been shown to be of comparable frequency in BL and DLBCL, highlighting the 319 overlap between these two entities (37) . 320
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321
The Lymphopanel highlights a unique PMBL mutational signature 322 STAT6 and SOCS1 mutations were both very significantly enriched in PMBL (FDR=6.8x10 -14 323 and FDR=2.5x10 -5 respectively), with STAT6 being the most frequently mutated gene in 324 PMBL (72.2%, Figures 3 and S5C ). All STAT6 mutations were non-synonymous SNVs and 325 recurrent variants were frequent among PMBL, including seven N417 variants ( Figure S7) . 326 SOCS1 mutations were present in 55.5% of PMBL patients, 30% of them harboring SOCS1 327 inactivating mutations ( Figure S5C ). TNFAIP3 mutations have also been frequently identified 328 in PMBL (up to 36%)(38). We found TNFAIP3 mutations to be significantly enriched in 329 PMBL (61.1%, FDR=3.1x10 -5 ), with all but one TNFAIP3 mutated PMBL patient harboring 330 truncating mutations (Figures 3 and S5C ). The frequent TNFAIP3 and SOCS1 mutations in 331 PMBL highlight the similarities between PMBL and cHL(38,39). Furthermore, no MYD88, 332 CD79B or CARD11 mutations were observed in PMBL patients (Figure 1 ), suggesting a 333 PMBL dependence on TNFAIP3 mutations for the constitutive activation of NFkB. 334
Interestingly, significant GNA13 mutation enrichment was shown in PMBL rather than GCB 335 in our cohort (50%, FDR=2.8x10 -4 ) (Figures 3 and S5) , and one third of GNA13 variants were 336 potentially truncating mutations (Figure 4) . 337
We discovered 46 B2M variants in 18.1% of total patients, significantly enriched in PMBL 338 (50%, FDR=1.2x10 -3 ) (Figures 1, 3 and S5C ). Six of nine B2M mutated PMBL patients 339 harbored truncating mutations and the remaining three presented pathogenic non-synonymous 340 SNVs, two of which were a highly recurrent p.M1R variant predicted to affect the start codon 341 ( Figure 4) . Recently, frequent B2M mutations leading to lack of protein expression were 342 identified in cHL(9). Our similar findings in PMBL further highlight the molecular 343 similarities between these two entities. CD58 variants were also significantly enriched in 344 PMBL (FDR=1.2x10 -3 ) (Figures 3 and S5) , with five of seven CD58 mutated PMBL patients 345 exhibiting truncating mutations, potentially leading to a lack of CD58 expression. 346 Importantly, PD-1 blockade has recently shown promise as an effective treatment of relapsed 347 or refractory cHL(40). Escape from T cell immunity via B2M and/or CD58 mutations could 348 potentially affect the activity of PD-1 inhibitors in PMBL and cHL and warrants further 349 investigation. Furthermore, we found 39 CIITA variants, enriched in PMBL as well (55.6% of 350 PMBL versus 14.14% of total patients, FDR=3.1x10 -5 ) (Figures 1, 3 cell survival, associated with specific overexpression of proapoptotic Bim protein(42). We 362 found 48 ITPKB variants, present in 14% of total patients (Figures 1 and S5) . ITPKB 363 mutations were uniformly distributed along the protein sequence, excepting the seemingly 364 conserved catalytic IPK domain, affected by only two non-synonymous SNVs (Figure 4) . 365
MFHAS1 is a potential oncogene with highly conserved leucine-rich tandem repeats, isolated 366 from a minimal common amplified region in malignant fibrous histiocytomas at 8p23.1. 367 MFHAS1 is also a target gene for chromosomal translocation t(8;14)(p23.1;q21) in B-cell 368 lymphoma cell lines and has been shown to be tumorigenic in nude mice(43). In our cohort, 369 MFHAS1 variants were identified in 7.9% of total patients, and were distributed 370 homogeneously along the coding sequence, with no recurrent mutations identified (Figure 4) . 371
Although the role of these potential oncogenes in lymphomagenesis is still unclear, their high 372 mutation frequency in PMBL especially warrants further investigation. 373
As for XPO1, it encodes CRM1, an exporter of several tumor suppressor proteins (TSPs). 374
Cytoplasmic export of TSPs renders them inactive, indicating that XPO1 acts as a proto-375 oncogene. XPO1 mutations were present in 4.7% of total patients (1.2% of ABC, 1.2% of 376 GCB, 3% of "other" and 38.9% of PMBL) (Figures 1 and S5) . The mutation identified is 377 recurrent, with all variants affecting E571 (Figure 4 ), as previously found in rare CLL cases 378 (<5%)(44). Importantly, Selective Inhibitors of Nuclear Export (SINEs), have been shown to 379 effectively target CRM1 and retain TSPs in the nucleus(45). Given the frequency of XPO1 380 E571 mutations in PMBL, further investigation concerning their impact on response to SINEs 381 is warranted (Jardin et al, under review). 382 383
Identification of gene mutations correlated with clinical characteristics and prognosis 384
We tested each gene in the Lymphopanel for correlation with clinical characteristics including 385 age, stage, IPI, bone marrow involvement and presence of bulky disease. 386 CD79B, KMT2D and MYD88 mutations were significantly correlated with age ( Figure S8) . 387 12 higher age of ABC patients (p=1.01x10 -7 in our cohort)(46). As for KMT2D mutations, 389 homogenous among subtypes, this result potentially suggests an accumulation of passenger-390 type mutations, particularly visible in this long gene (16.6 kb sequenced). MYD88 mutations 391
were also significantly correlated with higher IPI (FDR=0.04). 392
On the other hand, PMBL patients were significantly younger (p=1.21x10 -8 ) and the large 393 majority of genes whose mutations were significantly enriched in PMBL were also correlated 394 with younger age ( Figure S8 ). In addition, B2M and immunity pathway mutations were 395 significantly inversely correlated with Ann Arbor stage (FDR=3.2x10 -3 and FDR=0.045 396 respectively), and B2M and STAT6 mutations were significantly inversely correlated with IPI 397 (FDR=5.5x10 -4 and FDR=0.026 respectively). 398
As expected, OS and PFS decreased with increasing IPI and ABC patients displayed 399 significantly worse OS and PFS than GCB patients in the R-CHOP treatment group 400 (p=1.9x10 -2 and p=6.6x10 -3 respectively) ( Figure S9 ). Of note, PMBL patients in our cohort 401 did not present the favorable prognosis typically associated with this subtype(47), perhaps due 402 to the lack of dedicated treatment. 403
Prognostic impact was assessed for all Lymphopanel genes and subtypes, among patients 404 treated with R-chemotherapy, separated into an R-CHOP group and an R-ACVBP group. 405
Analyses over all subtypes were performed using multivariate Cox tests, while analyses of 406 each subtype individually were performed using log-rank tests. In both cases, independent 407 corrections of p-values were performed for OS and PFS. Gene mutations harboring prognostic 408 impacts with uncorrected p-values < 0.05 are highlighted in Table 1 and Figure S10 , and all 409 survival analyses are presented in Table S7 . We set an FDR threshold of 0.05 to detect gene 410 mutations with significant prognostic impacts. 411
Among ABC DLBCL treated with R-CHOP, TNFAIP3 mutations were significantly 412 associated with lower OS (FDR=7.86x10 -4 ) and PFS (FDR=3.04x10 -2 ), while GNA13 413 mutations were significantly associated with lower PFS (FDR=3.04 x10 -2 ), ( Figure 5 ). Of 414 note, the poor prognostic impact of these mutations was not observed in patients treated with 415 R-ACVBP, which, for TNFAIP3 at least, might be linked to the improved survival observed 416 in younger patients with DLBCL treated with R-ACVBP(48). These findings need to be 417 confirmed in an independent cohort of patients, given the small sample size. 418
Unfortunately, the prognostic impact of TNFAIP3 mutations in PMBL patients could not be 419 assessed due to the existence of only one WT TNFAIP3 PMBL patient treated with R-CHOP 420 (Table S7 ). Moreover, previously described prognostic impacts of TP53, FOXO1 or MYD88 421
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424
In conclusion, NGS is increasingly accessible in academic research settings, but its 425 possibilities in routine clinical settings have yet to be thoroughly harnessed. This study has 426 shown that, by using a restricted set of genes, not only can well-known mutations be tracked, 427 but novel or rare mutations can also be identified and potentially targeted as well. Detailing in the total cohort are represented as a stacked bar chart. The number at the top of each bar 460
represents the mutation frequency of the indicated gene in the total cohort. Bars are 461 subdivided by DLBCL subtype, with segments proportional to mutation frequency. 462
Potentially actionable targets are highlighted by indicating the appropriate class of molecule, 463 which could potentially be used. 464 per subtype are shown here as the percentage of the total number of patients. Statistical 476 significance of gene mutation enrichment in a given subtype is indicated by the FDR column. 477
The horizontal line separates genes with FDR<0.05, considered significant, from genes with 478 FDR≥0.05. 479 domains imported from the Pfam database (green). Exons were located using the CCDS 481 database and were numbered automatically, not counting non-coding and spliced exons. 482
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